AIM: To explore the effects of peptide S-8300 from shark liver (S-8300) on liver function as well as in regulating immune functions in experimental injury models. METHODS: Mice were administered with different doses of S-8300 for four consecutive days, followed by mice injected with tetrachloromethane (CCI4) on d 3. The activity of ALT, AST, LDH, SOD and contents of MDA and GSH in the mice liver were tested. And mice were treated with Cy (100 mg/kg) at the beginning of the experiment to induce immunosuppression model. The S-8300 groups were treated with S-8300 seven days after the beginning of Cy administration. The effects of S-8300 on the formulation of serum hemolysin and the content of IL-2 in serum in the immunosuppression mice were observed. RESULTS: S-8300 obviously decreased the level of ALT (52.2±11.0 U/dL vs135.9±6.5 U/dL, P<0.01), AST (67.5±6.9 U/dL vs 238.8±8.7 U/dL, P<0.01), LDH (155.1±46.8 U/dL vs 240.4±6.0 U/dL, P<0.01) & MDA (0.64?.027 nmol/mg vs 1.06±0.040 nmol/mg, P<0.01) and increased SOD (24.51±1.01 U/mg vs 19.05±0.73 U/mg, P<0.01) & GSH (24.17±0.91 μg/mg vs 14.93±0.45 μg/mg, P<0,01) in mice liver damaged by CCI4. S-8300 also markedly improved the formulation of serum hemolysin (0.094±0.005 A540 vs 0.063±0.006 A540, P<0.01) and increased the level of IL-2 (9.74±1.16 pg/mL vs 5.81±0.87 pg/mL, P<0.01) in serum of the immunosuppression mice. CONCLUSION: The results suggested S-8300 has significant hepatoprotective, immunomodulatory and inhibiting of lipid peroxidation activity. AIM: To explore the effects of peptide S-8300 from shark liver (S-8300) on liver function as well as in regulating immune functions in experimental injury models. METHODS: Mice were administered with different doses of S-8300 for four consecutive days , followed by mice injected with tetrachloromethane (CCI4) on d 3. The activity of ALT, AST, LDH, SOD and contents of MDA and GSH in the mice liver were tested. And mice were treated with Cy (100 mg / kg) at The beginning of the experiment to induce immunosuppression model. The S-8300 groups were treated with S-8300 seven days after the beginning of Cy administration. The effects of S-8300 on the formulation of serum hemolysin and the content of IL-2 in RESULTS: S-8300 significantly decreased the level of ALT (52.2 ± 11.0 U / dL vs. 135.9 ± 6.5 U / dL, P <0.01), AST (67.5 ± 6.9 U / dL vs 238.8 ± 8.7 U / dL, P <0.01), LDH (155.1 ± 46.8 U / dL vs 240.4 ± 6.0 U / dL, P <0.01) (P <0.01) and increased SOD (24.51 ± 1.01 U / mg vs 19.05 ± 0.73 U / mg, P <0.01) and GSH (24.17 ± 0.91 μg / mg vs 14.93 ± 0.45 μg / ) in mice with liver damaged by CCI4. S-8300 also markedly improved the formulation of serum hemolysin (0.094 ± 0.005 A540 vs 0.063 ± 0.006 A540, P <0.01) and increased the level of IL-2 (9.74 ± 1.16 pg / mL vs 5.81 ± 0.87 pg / mL, P <0.01) in serum of the immunosuppression mice. CONCLUSION: The results suggested that S-8300 has significant hepatoprotective, immunomodulatory and inhibiting of lipid peroxidation activity.